Mundel Thomas M, Schaefer Karl-Ludwig, Colombo-Benkmann Mario, Dietl Karl-Heinz, Diallo-Danebrock Raihana, Senninger Norbert
Division of Matrix Biology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215, USA.
Cancer Biol Ther. 2007 Nov;6(11):1700-3. doi: 10.4161/cbt.6.11.5165. Epub 2007 Oct 13.
Renal cell carcinoma (RCC) occurring in renal allografts after cadaveric kidney transplantation has rarely been observed. RCC accounts for 2.3% of all malignancies in the general population, but up to 4.8% of malignancies in renal transplant recipients. Most have been reported in the patient's own diseased kidneys, whereas RCC in the renal allograft occur in only 10%. Here, we describe an organ-preserving surgical technique of a malignant renal tumor in a kidney allograft using a harmonic scalpel (Ultracision) for tumor enucleation. Furthermore we demonstrate by DNA microsatellite analysis the tumor's genetic origin as donor related. Collectively, we suggest that patients with a well defined low grade RCC in the kidney allograft and altogether low malignancy and good allograft function should only undergo an organ-preserving procedure and short-term postoperative screening.
尸体肾移植后肾移植受者发生肾细胞癌(RCC)的情况鲜有报道。RCC在普通人群的所有恶性肿瘤中占2.3%,但在肾移植受者的恶性肿瘤中占比高达4.8%。大多数病例报道的是患者自身患病的肾脏发生RCC,而肾移植肾中发生RCC的仅占10%。在此,我们描述了一种使用超声刀(超声切割止血刀)对肾移植肾中的恶性肾肿瘤进行肿瘤剜除的保器官手术技术。此外,我们通过DNA微卫星分析证明肿瘤的遗传起源与供体相关。我们共同建议,对于肾移植肾中明确诊断为低级别RCC、总体恶性程度低且移植肾功能良好的患者,仅应接受保器官手术及术后短期筛查。